Multicentre randomized phase II study of neoadjuvant trastuzumab plus docetaxel with and without bevacizumab and trastuzumab plus docetaxel plus non-pegylated liposome-encapsulated doxorubicin (NPLD) with and without bevacizumab in HER2-positive early breast cancer [Multizentrisch randomisierte Phase II Studie für neoadjuvantes Trastuzumab plus Docetaxel plus nicht pegyliertes liposomal verkapseltes Doxorubicincitrat (NPLD) mit und ohne Bevacizumab bei HER2-positivem frühem Mammakarzinom].

Trial Profile

Multicentre randomized phase II study of neoadjuvant trastuzumab plus docetaxel with and without bevacizumab and trastuzumab plus docetaxel plus non-pegylated liposome-encapsulated doxorubicin (NPLD) with and without bevacizumab in HER2-positive early breast cancer [Multizentrisch randomisierte Phase II Studie für neoadjuvantes Trastuzumab plus Docetaxel plus nicht pegyliertes liposomal verkapseltes Doxorubicincitrat (NPLD) mit und ohne Bevacizumab bei HER2-positivem frühem Mammakarzinom].

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Doxorubicin liposomal (Primary) ; Docetaxel; Trastuzumab
  • Indications Early breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 23 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Sep 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top